Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Alector Inc
0Z2Current price
5.3 EUR
+0.32 EUR (+6.43%)
Last closed
5.13 USD
Company
www.alector.com
ISIN
US0144421072
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
563 112 448 USD
Yield for 12 month
+23.68 %
1Y
3Y
5Y
10Y
15Y
0Z2
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Address: 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
13.75 USDP/E ratio
–Dividend Yield
–Current Year
+97 062 000 USD
Last Year
+133 617 000 USD
Current Quarter
+15 342 000 USD
Last Quarter
+15 083 000 USD
Current Year
+88 214 000 USD
Last Year
+133 617 000 USD
Current Quarter
+15 342 000 USD
Last Quarter
+12 802 000 USD
Key Figures 0Z2
1 year
3 years
5 years
10 years
EBITDA
-177 394 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-19.25 %
PEG Ratio
–
Return On Equity TTM
-112.55 %
Wall Street Target Price
13.75 USD
Revenue TTM
61 508 000 USD
Book Value
1.21 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
68.4 %
Dividend Yield
–
Gross Profit TTM
-76 801 000 USD
Earnings per share
-1.71 USD
Diluted Eps TTM
-1.71 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
-86.3 %
Profit Margin
-257.54 %
Dividend Analytics 0Z2
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0Z2
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 0Z2
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
526.3158
Enterprise Value Revenue
2.2851
Price Sales TTM
9.1551
Enterprise Value EBITDA
-8.3996
Price Book MRQ
4.7347
Financials 0Z2
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 0Z2
For 52 weeks
3.66 USD
8.9 USD
50 Day MA
5.07 USD
Shares Short Prior Month
4 145 007
200 Day MA
5.44 USD
Short Ratio
8.17
Shares Short
4 845 433
Short Percent
7.1 %
BeatStart